Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Leukemia 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Cyclophosphamide 12aldesleukin 9fludarabine 8fludarabine phosphate 7pembrolizumab 6Ipilimumab 5Interleukin-2 5Nivolumab 4dabrafenib 2Vemurafenib 2Biopsy 2Aminolevulinic Acid 2varlilumab 1trametinib 1tilsotolimod 1spartalizumab 1sotigalimab 1sonidegib 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1glembatumumab vedotin 1eprenetapopt 1epacadostat 1encorafenib 1cemiplimab 1cabozantinib 1binimetinib 1bempegaldesleukin 1abobotulinumtoxinA 1X-Rays 1Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Skin Neoplasms × Interleukin-15 × Clear all
NCT01369888 2015-01-27

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 8 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡